Brilinta, a new antiplatelet drug
You'll hear lots of buzz about Brilinta, a new antiplatelet drug.
Brilinta (ticagrelor) will compete with Plavix (clopidogrel) and Effient (prasugrel)...for acute coronary syndrome or after a stent.
Plavix will still lead the pack...for a while. It was the first one approved and is used the most. But it's not perfect.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote